Full Press Release Details
PITTSBURGH , March 19, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS ) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030.
Executive Commentary
"Over the past several years, we have taken decisive actions to strengthen the foundation of Viatris by simplifying the portfolio, strengthening the balance sheet and stabilizing the base business," said Scott A. Smith , CEO, Viatris . "Today, we are entering the next phase of our evolution. With a growing base business, multiple anticipated near-term launches, a promising innovative pipeline and the financial flexibility to pursue disciplined accretive business development, we believe Viatris is well positioned to deliver sustained revenue and earnings growth through the end of the decade while continuing to create value for patients and shareholders."
"Our diversified portfolio and strong cash flow generation provide significant financial flexibility to invest in growth while maintaining a disciplined capital allocation framework," said Doretta Mistras , CFO, Viatris . "We expect to have more than $11 billion in cash available for deployment through 2030, which would enable us to return capital to shareholders and pursue accretive business development to further strengthen our long-term growth profile."
Key Elements to be Highlighted at the Investor Event
During the event, the Company will highlight key elements supporting its long-term growth targets, including its:
The Company believes these elements collectively support its framework for delivering sustained revenue and earnings growth through 2030.
Long-Term Financial Targets and Capital Allocation
At the event, the Company will also outline its long-term financial targets through 2030, including the capital allocation framework intended to support its future growth.
For its Combined Long-Term Targets through 2030, the Company expects to deliver 5% to 6% Total Revenues CAGR, 7% to 8% Adjusted EBITDA CAGR, 9% to 10% Adjusted EPS CAGR and more than $3 billion in annual free cash flow in 2030.
The Combined Long-Term Targets are comprised of the Company's Base Case Long-Term Targets and Potential Additional Drivers.
For its Base Case Long-Term Targets through 2030, Viatris expects its base business, supported by anticipated upcoming launches of value-added medicines, to deliver 3% to 4% Total Revenues CAGR, 4% to 5% Adjusted EBITDA CAGR, including operating leverage from the cost savings resulting from its Enterprise-Wide Strategic Review, 6% to 7% Adjusted EPS CAGR, including the benefit from future expected share repurchases, and more than $2.7 billion in annual free cash flow in 2030.
As part of its recently completed Enterprise-Wide Strategic Review, Viatris identified approximately $650 million in gross cost savings over a three-year period, with up to $250 million expected to be reinvested in the Company.
Potential Additional Drivers include expected growth from accretive business development and the potential launches of selatogrel and cenerimod.
The Company expects more than $11 billion in cash available for deployment through 2030 under its Base Case Long-Term Targets and has assumed that approximately 50% of the cash available for deployment through 2030 will be allocated to disciplined accretive business development.
| Potential Additional Drivers | |||||||
| Base Case Long-Term Targets (1) | Selatogrel and Cenerimod | Accretive Business Development | Combined Long-Term Targets (1) | ||||
| Total Revenues CAGR (2) | 3% - 4% | +1 % | +1 % | 5% - 6% | |||
| Adjusted EBITDA CAGR (2) | 4% - 5% | – | +3 % | 7% - 8% | |||
| Adjusted EPS CAGR (2) | 6% - 7% | – | +3 % | 9% - 10% | |||
| Free Cash Flow in 2030 | >$2.7B | >$3.0B |
| (1) | Targets and Potential Additional Drivers do not represent the Company's financial guidance. The targets are subject to numerous assumptions, risks and uncertainties, including many that are outside of the Company's control, and actual results may differ materially. All constitute forward-looking statements, and you should not place undue reliance on the discussion of them. See "Forward-Looking Statements." |
| (2) | Five-year compound annual growth rate ("CAGR") long-term targets comparing 2025 to 2030E are based on budgeted exchange rates. See "Key Exchange Rates" for more information. |
Investor Event Webcast
A live webcast of the Investor Event will begin today at 10:00 a.m. ET and can be accessed on the Company's website at investor.viatris.com . Presentation materials and a replay of the webcast will also be available on the Company's website.
Certain Key Terms and Presentation Matters
Revenue and Earnings : Refers to Total Revenues, Adjusted EBITDA and Adjusted EPS.
Key Exchange Rates Our 2026 financial guidance and long-term financial targets are based on the following budgeted exchange rates: Euro ($/EUR) 0.87, China Renminbi ($/CNY) 7.19, Japanese Yen ($/JPY) 144.35, and Indian Rupee ($/INR) 85.80.
Viatris Inc. (Nasdaq: VTRS ) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com , and connect with us on LinkedIn , Instagram , YouTube and X .
Forward-Looking Statements
For more detailed information on the risks and uncertainties associated with Viatris Inc. ("Viatris" or the "Company"), see the risks described in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. You can access Viatris' filings with the SEC through the SEC website at www.sec.gov or through our website and Viatris strongly encourages you to do so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this press release or our filings with the SEC. Viatris undertakes no obligation to update any statements herein for revisions or changes after the date of this press release other than as required by law.
Non-GAAP Financial Measures
This press release includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, and adjusted EPS are presented in order to supplement investors' and other readers' understanding and assessment of the financial performance of Viatris. Free cash flow refers to U.S. GAAP net cash provided by operating activities less capital expenditures. Adjusted EBITDA refers to as U.S. GAAP net earnings (loss) adjusted for income tax provision (benefit), interest expense and depreciation and amortization (to calculate EBITDA) and further adjusted for share-based compensation expense, litigation settlements and other contingencies, net, loss on divestitures of businesses, impairment of goodwill and restructuring, acquisition and divestiture related and other special items. Adjusted EPS refers to adjusted net earnings divided by the weighted average number of diluted shares of common stock outstanding. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.
Long-Term Financial Targets
The Company is not providing forward-looking information for U.S. GAAP net (loss) earnings, EPS or U.S. GAAP net cash provided by operating activities or a quantitative reconciliation of its long-term targets for adjusted EBITDA CAGR, adjusted EPS CAGR and free cash flow to their most directly comparable U.S. GAAP measures, U.S. GAAP net earnings (loss) CAGR, EPS CAGR and U.S. GAAP net cash provided by operating activities, respectively, because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired IPR&D and certain other gains or losses, including for the fair value accounting impact for equity investments, as well as related income tax accounting because certain of these items have not occurred, are out of the Company's control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the relevant periods.
SOURCE Viatris Inc.